FDA approves Roche’s OCREVUS® (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive multiple sclerosis

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice